Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer
Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer. // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000501?dgcid=rss_sd_all
Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer. International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000501?dgcid=rss_sd_all
“Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer.” International Journal of Lung Cancer.
@article{article89528,
title = {Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000501?dgcid=rss_sd_all}
}